-
Results from INTRIGUE trial – Ripretinib
Deciphera has announced the topline results of the INTRIGUE trial examining the use of QINLOCK in the 2L setting. Please find a link to the press release here for your review. A paper written by Dr John Zaleberg et al. is available here: https://theoncologist.onlinelibrary.wiley.com/doi/10.1002/onco.13917 Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced […]
Continue reading -
Survey on Mutation Analysis
Boston University School of Medicine is conducting a study regarding GIST patients’ understanding of tumor testing and personalized medicine. Feel free to read more below! The direct link to the survey is: https://bostonu.qualtrics.com/SE/?SID=SV_0MMOLgR37hBH1t3 For any questions or comments, please contact the researchers directly.
Continue reading -
2014 NIH Wildtype GIST Clinic
For more information about the NIH clinic for pediatric & wildtype GIST, see our webpages about past clinics. Patients of all ages with wildtype GIST are encouraged to participate. Participation enables the patient to receive special tests and consultations with wildtype GIST experts from numerous hospitals as well as the NIH staff physicians and researchers.
Continue reading -
Combination trial imatinib + MEK162
New combination trial for GIST: imatinib plus MEK inhibitor MEK162 A new clinical trial opened in November 2013 at Memorial Sloan-Kettering Cancer Center to test the combination of imatinib (Gleevec) plus MEK162, an inhibitor of the MEK pathway. Trial NCT01991379, A Phase Ib/II Study of MEK162 in Combination With Imatinib Mesylate in Patients With Untreated […]
Continue reading -
GIST News from 2012 ASCO
Becky Bensanhaver and Nancy Berezin attended the ASCO meeting in June 2012 on behalf of GIST Support International and all GIST patients. This is an effort reqiuring stamina, comfortable shoes, and keen attention to cover the huge meeting and absorb the new information. MANY THANKS to Nancy and Becky for their hard work! LINK HERE to […]
Continue reading -
Regorafenib Approved
FDA Approves Stivarga (regorafenib) for GIST On February 25, 2013 the FDA approved regorafenib (brand name Stivarga) for treatment of GIST patients with “advanced gastrointestinal stromal tumors (GIST) that cannot be surgically removed and no longer respond to other FDA-approved treatments for this disease” (Gleevec and Sutent). This makes regorafenib the first drug approved for third-line treatment of […]
Continue reading -
Votrient approved for sarcoma
On April 26, 2012 the FDA announced approval of pazopanib (votrient) for soft tissue sarcoma. Earlier the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee voted March 20, 2012 to approve a New Drug Application for pazopanib tablets (Votrient, GlaxoSmithKline) in the treatment of patients with advanced soft tissue sarcoma who have received previous chemotherapy. […]
Continue reading -
FDA approves adjuvant Gleevec extension to 3 years
FDA news release, Jan 31, 2012: FDA approves Gleevec for expanded use in patients with rare gastrointestinal cancer Confirmatory trials show significantly prolonged survival in patients; drug granted regular approval The U.S. Food and Drug Administration today granted Gleevec (imatinib) regular approval for use in adult patients following surgical removal of CD117-positive gastrointestinal stromal tumors […]
Continue reading -
Dana-Farber Brigham & Women’s GIST Celebration
Dana-Farber Hosts Celebration for GIST Patients and Families By Terry Jennings “Uplifting” is the word my husband, Lou, used to describe the Dana-Farber celebration: Living with GIST, 10 Years of Molecular Targeted Therapy. It was truly uplifting to hear the physicians relate stories of the battle with our rare cancer; to be in the same […]
Continue reading -
GIST News from 2011 ASCO
Becky Bensenhaver and Nancy Berezin, both members of GIST Support International’s Science Committee, attended the 2011 meeting of ASCO (American Society of Clinical Oncology) in Chicago in early June. Becky was fortunate to receive an ASCO scholarship to pay expenses, thus enabling our team to cover the huge convention to catch the news on treatment […]
Continue reading